linjc16/ctgov huggingface dataset:
Care of Child's Hygiene From Zero to Two Years Old

Study Overview
=================
Brief Summary
-----------------
This study aimed to identify the perceptions of family caregivers and professionals of the Family Health Strategy (FHS) for health care for children from 0 to 2 years, and actions on this issue developed by the FHS.

Detailed Description
-----------------
This study aimed to identify the perceptions of family caregivers and professionals of the Family Health Strategy (FHS) for health care for children from 0 to 2 years, and actions on this issue developed by the FHS. Chosen by a descriptive exploratory with a qualitative approach, consisting of 19 subjects while they were 9 professionals and 10 family caregivers. For data collection was used a semi-tour interview and for the treatment of empirical data, the technique of content analysis recommended by Bardin. For presentation and discussion of results the categories from the speech made the interviewers grouped as the possibility of confrontation between the speaches of the two groups, total of 6 categories: hygienist model: focus on personal hygiene, model medicocêntrico x extended care, environmental risk: the care with hygiene and socioeconomic conditions, family and life experience influence care with hygiene, process work x on caregiver perception of guidance received by the health service, link child / caregiver. The perceptions found in the discourse of professionals and caregivers showed that the biologically vision and focus on the body prevalent in health care, and that such care is still centered in the figure of the doctor because of the historical and cultural hegemony curative.

Official Title
-----------------
Care of Child's Hygiene From Zero to Two Years Old: Health Professionals' Perceptions of the Strategy and the Family Caregivers

Conditions
-----------------
Children Health Under Two Years Old, Health Professionals

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children under two years old professional member of the healthcare team Exclusion Criteria: caregivers who were not relatives children who had any physical impairment and/or mental

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children, Health Professionals<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Family Health Program, Hygiene, Child Health
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.

Detailed Description
-----------------
Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with delayed first phase insulin release. Improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.

Official Title
-----------------
Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial

Conditions
-----------------
Reactive Hypoglycemia

Intervention / Treatment
-----------------
* Drug: Sitagliptin phosphate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia Must be able to swallow tablet Negative pregnancy test (when appropriate) Exclusion Criteria: Renal insufficiency Hepatic insufficiency Diabetes (any type)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sitagliptin<br> | Drug: Sitagliptin phosphate<br>* Sitagliptin phosphate 100 mg per day per 2 weeks<br>* Other names: Januvia;|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo 1 tablet per day per 2 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical improvement assessed by a validated questionnaire |  | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose, insulin, GLP1, GIP |  | First and last evaluations | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Reactive hypoglycemia, Sitagliptin, Glucagon-Like Peptide 1, Incretins, Prediabetes
Effects of Therapeutic Touch on Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the efficacy of the Kreiger/Kunz method of Therapeutic Touch on function, pain perception and quality of life in persons with Osteoarthritis in the knee.

Conditions
-----------------
Osteoarthritis in the Knee

Intervention / Treatment
-----------------
* Other: Therapeutic Touch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons diagnosed with or exhibiting signs of osteoarthritis of at least one knee. Exclusion Criteria: Persons with connective tissue disorder Persons with bilateral total joint replacement of the knee Persons with dementia Persons with a systemic illness producing joint symptoms

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Arm 1<br>This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care | Other: Therapeutic Touch<br> <br> |
| No Intervention: Arm 2<br>Standard of Care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SF36 |  | 8, 12, 16 weeks | 
| WOMAC |  | 8, 12 and 16 weeks |
Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.

Detailed Description
-----------------
Bone diseases have been recognized recently as complications of genetic hemochromatosis. Further studies are needed to describe the role of iron in bone injuries. The purpose of this study is to describe bone status on patients with genetical hemochromatosis, at diagnostic time and his evolution under treatment.

Official Title
-----------------
Bone Status on Patients With Genetic Hemochromatosis : a 3 Years Descriptive and Evolutionary Study.

Conditions
-----------------
Genetic Hemochromatosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between 18 and 80 years C282 homozygosity Exclusion Criteria: corticosteroids during the last 3 months following treatments during the last 6 months : anabolic steroids, growth hormone, hormone therapy for menopause, tibolone, raloxifene. following treatments during inclusion or in the last 6 month : teriparatide, parathormone, fluor, strontium ranelate, biphosphonate. cancer or evolutionary hemopathy (including monoclonal gammopathy) pregnancy at inclusion time treated osteoporosis patient in wich follow up seems hard inclusion in another study incompatible with this one

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone mineral density | Vertebral and hips Dual energy X-ray Absorptiometry (DXA) | Change from baseline in bone mineral density at three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive value of iron overload on Bone Mineral Density |  | 1 day | 
| Number of vertebral fractures |  | 3 years | 
| Number of peripheral fractures |  | 3 years | 
| Number and location of joint lesions detected by the examination (pain and swelling) |  | 3 years | 
| Determination of genetic polymorphism of BMP 2 and 4 |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetic hemochromatosis, Iron overload, C282 homozygosity
Parathyroid Hormone for the Treatment of Humerus Fractures

Study Overview
=================
Brief Summary
-----------------
Hypothesis: The investigators want to study whether parathyroid hormone improves healing of humerus after a fracture. The investigators will assess healing of the humerus with Constant score.

Official Title
-----------------
Phase IV Study of the Effect of Parathyroid Hormone on Fractures of the Humerus

Conditions
-----------------
Shoulder Fractures

Intervention / Treatment
-----------------
* Drug: 1-84 parathyroid hormone
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: proximal humeral fracture eligible for conservative treatment. able to understand the protocol signs an informed consent Exclusion Criteria: liver disease kidney disease severe osteoporosis malignant disease bone metabolic disease oral treatment with bisphosphonates during the last 3 months. treatment with Denosumab during the last 6 months. intravenous treatment with bisphosphonates during the last 12 months.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Saline injection daily for 8 weeks.<br>|
| Experimental: Parathyroid hormone<br> | Drug: 1-84 parathyroid hormone<br>* 100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in constant score | Constant score summarizes the function of the arm using a questionnaire (activities of daily living - ADL) and functional testing of the arm. | 5, 8, 11, 23, and 104 weeks. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Oxford Shoulder Score | Oxford shoulder score is a questionnaire that assesses the function of the arm through the evaluation of the participant. | 5, 8, 11, 23, and 104 weeks. | 
| Changes in bone formation evaluated by X-ray. |  | 5, 8, 11, 23, and 104 weeks. | 
| Changes in biochemical bone markers | sodium, potassium, creatinine, liver enzymes, vitamin D, parathyroid hormone, alkaline phosphatase, hemoglobin, magnesium, calcium, zinc. | 0, 5, 25 weeks | 
| Changes in regulatory T lymphocytes | Regulatory CD3+CD4+CD25+Foxp3+ T lymphocytes. | 0, 8, 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
proximal humeral fracture
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells. OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.

Official Title
-----------------
The Role of AF1q in Progression of Leukemia

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: gene expression analysis
* Genetic: gene rearrangement analysis
* Genetic: polymerase chain reaction
* Genetic: protein analysis
* Genetic: western blotting
* Other: laboratory biomarker analysis
* Other: mass spectrometry


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Cryopreserved acute myeloid leukemia specimens PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: gene expression analysis|nan|
|Genetic: gene rearrangement analysis|nan|
|Genetic: polymerase chain reaction|nan|
|Genetic: protein analysis|nan|
|Genetic: western blotting|nan|
|Other: laboratory biomarker analysis|nan|
|Other: mass spectrometry|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subcellular localization of the MLL-AF1q fusion protein in leukemia cells |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult acute myeloid leukemia, childhood acute myeloid leukemia/other myeloid malignancies
Personalized Sequence for Thoracic, Esophageal, and H&N Cancer

Study Overview
=================
Brief Summary
-----------------
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.

Detailed Description
-----------------
To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS, duration of response and overall survival) of patients with advanced cancer, the investigators are going to take a fresh tissue of patients and process molecular profiling.

Official Title
-----------------
Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Genetic: Genetic test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: metastatic, histologically confirmed NSCLC, head & Neck Cancer, Esophageal cancer Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation) | The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer | 3 years |
Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium Polyethylenimine Nanoparticles

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the antibacterial activity of crosslinked quaternary ammonium polyethylenimine (PEI) nanoparticles incorporated at 1-2% w/w in a commercial soft liner material when compared to the commercial soft liner material. The investigators' results in vitro showed a significant delay in bacterial growth. Therefore, the investigators assume to have the same delay in vivo- on patients.

Official Title
-----------------
Clinical Study of the Antibacterial Properties of the Nano Particles Which Incorporated With the Soft Liner Silicone - in Obturators

Conditions
-----------------
Carcinoma of Head and Neck

Intervention / Treatment
-----------------
* Device: polyethylenimine (PEI) nanoparticles.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients post maxillectomy, who are using obturators Exclusion Criteria: patients who are not using obturators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: soft liner with nano particles<br>the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion. | Device: polyethylenimine (PEI) nanoparticles.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial growth |  | a week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
head and neck carcinoma, obturators, maxillectomy, soft liner, nano particles, antibacterial properties, patients post maxillectomy
Behavioral Health Services for Women Receiving Public Assistance

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether access to behavioral health services has been affected by welfare reform.

Detailed Description
-----------------
This study examines patterns of behavioral health service use among a group of female household heads who receive Temporary Assistance to Needy Families (TANF) and have serious mental illness (SMI). The findings from this study will be used to determine the feasibility of conducting a full-scale longitudinal study of the impact of welfare reform outcomes on female household heads who have SMI and are currently or formerly recipients of welfare.

Official Title
-----------------
Access to Behavioral Health Services for Women on TANF

Conditions
-----------------
Mental Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female head of household on TANF at any time during first quarter of 1997 and used at least one behavioral health service during that quarter DSM IV diagnosis of serious mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Social Welfare, Mentally Ill Persons, Mental Health Services